Alto Neuroscience, Inc. (ANRO) bonds
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$24.91−2.21 (-8.15%)
Close on Nov 17, 2026Market cap $977.52MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$13.48M
$4.52M due within a year
Net debt
-$305.86M
After $319.34M of cash
Implied interest rate
18.28%
FY2025 interest ÷ average debt
Interest coverage
-26.9×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2024
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Alto Neuroscience's 10-Q for the period ended Jun 30, 2026
| Issue | Coupon | Amount issued | Carrying value |
|---|---|---|---|
| Amended Loan Agreement Convertible at $4 a share | Floating + 1.45% | $75.00M | $15.00M |
| Convertible debt Convertible | – | – | $2.00M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Loan and Security Agreement | $35.00M |
See a number that looks wrong?